Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis A/RES/73/3 44. Further commit to advancing that new research and innovation environment through global collaboration, including through existing World Health Organization mechanisms and initiatives; strengthening research capacity and collaboration through improving tuberculosis research platforms and networks across the public and private sectors, noting such platfor ms and networks as the Brazil, Russian Federation, India, China and South Africa (BRICS) Tuberculosis Research Network and the Life Prize; in basic science, clinical research and development, including pre-clinical and clinical trials, as well as operational, qualitative and applied research, to advance effective tuberculosis prevention, diagnosis, treatment, and care and actions on the economic and social determinants and impacts of the disease; 45. Promote tuberculosis research and development efforts a iming to be needs-driven, evidence-based and guided by the principles of affordability, effectiveness, efficiency and equity and which should be considered as a shared responsibility. In this regard, we encourage the development of new product development partnership models and, for multidrug-resistant tuberculosis, continue to support existing voluntary initiatives and incentive mechanisms that separate the cost of investment in research and development from the price and volume of sales, to facilitate equitable and affordable access to new tools and other results to be gained through research and development, and we acknowledge the need to establish additional incentives for the research and development of new products to treat multidrug-resistant tuberculosis and to encourage stewardship, conservation, and global access to such products in addition to rewarding innovation, welcome innovation and research and development models that deliver effective, safe and equitable solutions to the challenges presented by tuberculosis, including those that promote investment by all relevant stakeholders, including Governments, industry, non-governmental organizations and academics, and continue to support existing voluntary initiatives and incentive mechanisms that avoi d reliance on high price or high sales combinations and explore ways to support innovation models that address the unique set of challenges presented by tuberculosis, including the importance of the optimal use of medicines and diagnostic tools, while promoting access to affordable medicines and other health technologies; 46. Commit to mobilize sufficient and sustainable financing for universal access to quality prevention, diagnosis, treatment and care of tuberculosis, from all sources, with the aim of increasing overall global investments for ending tuberculosis and reaching at least 13 billion United States dollars a year by 2022, as estimated by the Stop TB Partnership and the World Health Organization, according to each country’s capacity and strengthened solidarity, including through contributions to the World Health Organization as well as voluntary mechanisms such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, including its replenishment, which provides 65 per cent of all international financing for tuberculosis; and to align within overall national health financing strategies, including by helping developing countries to raise domestic revenues and providing financial support bilaterally, at regional and global levels, towards achieving universal health coverage and social protection strategies, in the lead-up to 2030; 47. Commit to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to 2 billion dollars, in order to close the estimated 1.3 billion dollar gap in funding annually for tuberculosis research, ensuring that all countries contribute appropriately to research and development, to support quality research and development of new and the effective implementation of recently approved health technologies, and to strengthen the academic, scientific, public health and laboratory capacity needed to support research and development for 18-16895 9/10